Source-grounded facts extracted from REPLIGEN CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
REPLIGEN CORP reported first quarter ended March 31, 2026 results: revenue $194 million, EPS $0.15. Guidance reaffirmed.
“#1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic • GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year • Reiterating FY26 organic”
Karen A. Dawes was appointed as Lead Independent Director at REPLIGEN CORP.
“appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director”
Tony J. Hunt changed role as Executive Chair at REPLIGEN CORP.
“Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors”
Olivier Loeillot was elected as Member of the Board at REPLIGEN CORP.
“the Board elected Mr. Loeillot as a member of the Board”
Olivier Loeillot was appointed as President and Chief Executive Officer at REPLIGEN CORP.
“Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024”
REPLIGEN CORP shareholders approved Advisory Vote on Compensation of the Named Executive Officers at the 2024-05-16 meeting.
“The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 46,636,342 2,832,814 66,253 3,335,291”
REPLIGEN CORP shareholders approved Ratify the Appointment of Independent Registered Public Accounting Firm at the 2024-05-16 meeting.
“The results of the ratification were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 50,203,147 2,635,812 31,741 0”
REPLIGEN CORP shareholders approved Election of nine directors at the 2024-05-16 meeting.
“The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Tony J. Hunt 49,451,347 34,608 49,454 3,335,291 Karen A. Dawes 46,716,865 2,770,270 48,274 3,335,291 Nicolas M. Barthelemy 47,873,168 1,612,070 50,171 3,335,291 Carrie Eglinton Manner 49,392,147 95,997 47,265 3,335,291 Konstantin Konstantinov, Ph.D. 48,360,681 1,124,367 50,361 3,335,291 Martin Madaus, D.V.M., Ph.D. 45,950,040 3,534,764 50,605 3,335,291 Rohin Mhatre, Ph.D. 49,290,001 195,180 50,228 3,335,291 Glenn P. Muir 48,280,711 1,204,396 50,302 3,335,291 Margaret A. Pax 49,475,139 12,749 47,521 3,335,291”
REPLIGEN CORP reported first quarter of 2024, covering the three-month period ended March 31, 2024 results: revenue $151.3 million, net income $2.1 million, EPS $0.04. Guidance reaffirmed.
“Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03”
Margaret A. Pax was elected as Director at REPLIGEN CORP.
“the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).”
REPLIGEN CORP reported financial results for the fourth quarter and year end December 31, 2023.
“On February 21, 2024, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2023.”
REPLIGEN CORP incurred senior notes of $600 million aggregate principal amount with Wilmington Trust, National Association at 1.00% per annum maturing December 15, 2028.
“On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.”
REPLIGEN CORP entered into Indenture with Wilmington Trust, National Association, as trustee valued at $600 million aggregate principal amount (effective 2023-12-14).
“On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the "Company") issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the "New Notes") under an Indenture, dated December 14, 2023 (the "Indenture"), between the Company and Wilmington Trust, National Association, as trustee.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.